Search results for "Ladder"

THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.

2014

Scopo del lavoro Re-TUR is strongly advocated for T1G3, because of the high incidence residual disease and mainly the risk of substaging. Its real clinical value remains to be determined and the clinical factors that may influence the decision. Some authors suggest that when muscle is present in the specimen, re-TUR may be avoided. To evaluate if the presence of muscle or not at the first TUR in T1G3 bladder cancer makes a difference in recurrence, progression and cancer specific survival after re-TUR. Materiali e metodi In a large retrospective cohort of 2530 primary T1G3 initially treated with BCG, 953 (37.7%) had a re-TUR. According to the presence or not of muscle in the specimen of pri…

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

2008

OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test…

Expression of Heat Shock Protein in bladder cancers.

2005

Expression of Heat Shock Protein in bladder cancers.

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

Intravesical gemcitabine in superficial bladder tumours preliminary results of a phase I-II study

2003

INTRODUCTION & OBJECTIVES: Gemcttabme is a pro-drug requmng intracellular phosphorylation by deoxycytidine kinase to be activated. Preliminary experiences. suggesting the activtty and the good tolerability of the drug on superficial transitional cell carcinoma of the bladder (TCCB) when administered by intravesical route, have been recently published. The mm of the present study was to evaluate the ablative efftcacy of weekly intravesical instillations of gemcitabine against paptllary marker lesions left after TUR of superficial TCCB. The scientific background and the ethical acceptability of thts approach have been balidated by the European Organization for Research and Treatment ot Cancer…

Virtual Team Leadership and Collaborative Engineering Advancements

2009

Sacral neurostimulation and neuromodulation in urological practice

2000

The problems associated with treating various forms of lower tract dysfunction by electrical stimulation are reflected in the many years of basic and clinical research in this area. However, better understanding of both neuroanatomy and neurophysiology, and development of new technologies have led to further application of electrical current to restore impaired bladder function. Contemporary knowledge of the potential for both sacral neurostimulation and neuromodulation as a therapeutic option for lower urinary tract dysfunction is reviewed.

Synthese von 2-alkoxysubstituierten Oligo- und Poly(1,4-phenylenethenylen)en und 2-Arylbenzo[b]furanen mit Hilfe der Siegrist-Reaktion

1994

Synthesis of 2-Alkoxy Substituted Oligo- and Poly(1,4-phenyleneethylene)s and 2-Arylbenzo[b]furanes by Applying the Siegrist Reaction Alkylation of 2-hydroxy-4-methylbenzaldehyde (1) yields the 2-alkoxy-4-methylbenzaldehydes (2a-l) which can be easily transformed to the Schiff bases 3a-l. The intermolecular self-condensation in a strongly alkaline medium leads to the oligo- and poly(1,4-phenyleneethenylene)s (4a-i) with an outstanding regular constitution and overall (E)-configuration. The terminal N-arylamino group can be cleaved by hydrolysis generating the compounds 5a-i. An intramolecular condensation forming the benzo[b]furanes 6j,k is observed for 3j,k – due to the activated OCH2 grou…

A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease

2022

Microbiotas are the range of microorganisms (mainly bacteria and fungi) colonizing multicellular, macroscopic organisms. They are crucial for several metabolic functions affecting the health of the host. However, difficulties hamper the investigation of microbiota composition in cultivating microorganisms in standard growth media. For this reason, our knowledge of microbiota can benefit from the analysis of microbial macromolecules (DNA, transcripts, proteins, or by-products) present in various samples collected from the host. Various omics technologies are used to obtain different data. Metagenomics provides a taxonomical profile of the sample. It can also be used to obtain potential funct…

Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a…

2021

Two doses of propiverine ER (30 and 45 mg/d) are available for the treatment of overactive bladder (OAB) syndrome. We have explored factors associated with the initial dosing choice (allocation bias), the decision to adapt dosing (escalation bias) and how dosing relative to other factors affects treatment outcomes. Data from two non-interventional studies of 1335 and 745 OAB patients, respectively, receiving treatment with propiverine, were analyzed post-hoc. Multivariate analysis was applied to identify factors associated with dosing decisions and treatment outcomes. Several parameters were associated with dose choice, escalation to higher dose or treatment outcomes, but only few exhibited…